Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Waldenström’s Macroglobulinemia: frontline treatment

Alessandra Tedeschi • 15 Jun 2019
EHA 2019
Rare Diseases Waldenström’s Macroglobulinemia Bortezomib Ibrutinib

Alessandra Tedeschi, MD, of the Niguarda Cancer Center, Milan, Italy, discusses frontline treatment for Waldenström’s Macroglobulinemia. Dr Tedeschi specifically discusses the use of chemo-monotherapy, ibrutinib and bortezomib. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Alessandra Tedeschi

1:20
RESONATE-2: Ibrutinib for CLL 5-year follow-up
Alessandra Tedeschi • 21 Sep 2019
1:25
iLLUMINATE 4-year follow up: obinutuzumab w/ ibrutinib vs w/ chlorambucil
Alessandra Tedeschi • 22 Sep 2019
17:22
Varying efficacies of combination and monotherapies in CLL
Alessandra Tedeschi et al. • 21 Sep 2019
1:52
RESONATE: five-year follow-up of ibrutinib for CLL
Alessandra Tedeschi • 15 Jun 2019

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals